doi: 10.1186/s11671-016-1517-3 219
Clinical Evidence and Case Studies In a case study of a 24 year old woman with chronic and worsening paranoid-type schizophrenia that was generally unresponsive to anti-psychotic treatment, the addition of NAC supplementation improved the patients symptomatology in seven days
Therefore, modulating copper homeostasis and cuproptosis addresses a novel pathogenic axis that is not directly targeted by existing first-line drugs, suggesting the potential for synergistic or personalized therapeutic strategies
At the time, the FDA cited safety concerns and a lack of evidence supporting their efficacy
Longer term For longer repeated exposure, copper-related labs may be reviewed periodically with a clinician
It has been utilized in clinical trials to treat heart and kidney disease connected to hypertension and other chronic diseases by blocking MR signaling with MR antagonists (MRAs), which suppresses fibrosis in these organs as MRAs likely have cardio-protective effects by directly blocking cardiac and vascular MR (72, 73)